Tina lives in Tennessee with her husband and daughter. Tina suffered with pneumonia for nine months starting in October 2008. Doctors later diagnosed Tina with a rare and congenital condition, Alpha-1 Antitrypsin. The deficiency of Alpha-1 can cause lung diseases in adults, and therefore is referred to “genetic COPD.”
“I am doing great, I pace 24/7, and I carry my machine in a purse and half the time people don’t even know.” “I got to watch my daughter graduate high school and college. I didn’t give up and the pacers saved my life.” She says about her pacer.
The Avery Diaphragm Pacing System is an implanted phrenic nerve or diaphragm stimulator. It consists of surgically implanted electrodes and receivers with an external transmitter and antennas.
It can be implanted either cervically or thoracically using minimally-invasive techniques such as video-assisted (VATS) or thoracoscopic approaches.
The Avery Diaphragm Pacing System is the only diaphragm pacing system to have full premarket approval (PMA) from the US FDA and CE Marking privileges under the European Active Implantable Medical Device Directive for adult and pediatric use.
In addition, using small implanted radiofrequency receivers rather than electrode wires that pass directly through the skin may decrease a patient’s risk of infection and ongoing wound care management issues.
Avery has been commercially distributing diaphragm pacing systems since the early 1970’s. Since then, more than 2,000 patients have been implanted in over 40 countries establishing an unsurpassed record of safety and reliability. Due to their high reliability and cost effectiveness, the Avery pacers are reimbursed by Medicare and most private and government insurance around the world.